Septerna Executive Sells Significant Stock Holdings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: NASDAQ.COM
- Transaction Overview: Chief People Officer Samira Shaikhly sold 11,798 shares of common stock on May 26, 2026, for approximately $355,000, reducing her direct holdings by 93.7% to just 793 shares, indicating a potential lack of confidence in the company's stock.
- Transaction Context: The sale was executed at an average purchase price of $30.06 as per SEC Form 4 and occurred during a period of rising stock prices, reflecting Shaikhly's non-discretionary reduction under a pre-arranged Rule 10b5-1 trading plan.
- Company Financial Health: Septerna reported $522.1 million in cash, cash equivalents, and marketable securities at the end of Q1 2026, providing a runway for operations until at least 2029, although the executive's sell-off may raise concerns about the company's outlook.
- Market Reaction and Outlook: Despite the executive's sell-off, Septerna's stock rose due to positive clinical trial progress, hitting a 52-week high of $37.99 on June 24, indicating market confidence in its future, although analysts have not included it in their top investment picks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SEPN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SEPN
Wall Street analysts forecast SEPN stock price to fall
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 33.470
Low
25.00
Averages
33.14
High
43.00
Current: 33.470
Low
25.00
Averages
33.14
High
43.00
About SEPN
Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. It is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Septerna Executive Sells Significant Stock Holdings
- Transaction Overview: Chief People Officer Samira Shaikhly sold 11,798 shares of common stock on May 26, 2026, for approximately $355,000, reducing her direct holdings by 93.7% to just 793 shares, indicating a potential lack of confidence in the company's stock.
- Transaction Context: The sale was executed at an average purchase price of $30.06 as per SEC Form 4 and occurred during a period of rising stock prices, reflecting Shaikhly's non-discretionary reduction under a pre-arranged Rule 10b5-1 trading plan.
- Company Financial Health: Septerna reported $522.1 million in cash, cash equivalents, and marketable securities at the end of Q1 2026, providing a runway for operations until at least 2029, although the executive's sell-off may raise concerns about the company's outlook.
- Market Reaction and Outlook: Despite the executive's sell-off, Septerna's stock rose due to positive clinical trial progress, hitting a 52-week high of $37.99 on June 24, indicating market confidence in its future, although analysts have not included it in their top investment picks.
See More
Septerna Executive's Stock Sale Raises Concerns
- Executive Sell-off: Septerna's Chief People Officer Samira Shaikhly sold 11,798 shares of common stock on May 26 for approximately $355,000, resulting in a dramatic 93.70% reduction in her direct holdings from 83,044 to 793 shares, indicating a pressing need for liquidity.
- Transaction Structure: The shares sold were acquired through exercising vested stock options and immediately disposed of in the open market, suggesting that the transaction was structured for liquidity rather than increasing equity exposure, reflecting cautious sentiment from company executives regarding future stock performance.
- Market Performance Impact: Following Shaikhly's sell-off, Septerna's stock price reached a 52-week high of $37.99 on June 24, indicating positive market sentiment driven by the company's clinical trial progress, although the executive's sale may raise investor concerns about the company's outlook.
- Financial Overview: Septerna has a market capitalization of $1.35 billion, with trailing twelve-month revenue of $72.26 million and a net loss of $36.04 million; despite these losses, the company holds $522.1 million in cash and equivalents, sufficient to fund operations at least until 2029, demonstrating financial stability.
See More
Septerna Executive Sells Nearly 12,000 Shares: Implications for Investors
- Executive Sell-off: Samira Shaikhly, Chief People Officer of Septerna, sold 11,798 shares of common stock for approximately $355,000, resulting in a dramatic reduction of her holdings from 83,044 to 793 shares, a decrease of 93.70%, indicating a heightened need for liquidity within the company.
- Transaction Context: The shares were sold after exercising vested stock options, suggesting the transaction was structured for liquidity rather than increasing equity exposure, reflecting a cautious outlook on the company's future stock performance by the executive.
- Company Financials: Septerna has a market capitalization of $1.35 billion, with trailing twelve-month revenue of $72.26 million and a net loss of $36.04 million, highlighting the challenges and opportunities faced by the company in the clinical-stage biotechnology sector.
- Market Reaction and Outlook: Despite the executive sell-off, Septerna's stock price rose following positive clinical trial results, reaching a 52-week high of $37.99 on June 24, indicating market confidence in its future; however, analysts have not included it in their top investment picks.
See More
Septerna Executive Sells Shares, Reduces Holdings by 13.46%
- Transaction Overview: According to an SEC Form 4 filing, Septerna's SVP Daniel D. Long exercised and immediately sold 15,000 shares of Common Stock on June 22, 2026, with a transaction value of approximately $533,000, indicating executive liquidity management.
- Change in Holdings: This transaction reduced Long's direct holdings from 111,412 shares to 96,412 shares, a decrease of 13.46%, while indirect holdings remained at zero, reflecting a strategic adjustment in executive stock management.
- Continued Equity Exposure: Post-transaction, Long retains 96,412 shares of Common Stock and approximately 36,000 unexercised stock options, indicating ongoing confidence in Septerna despite the reduction in direct holdings.
- Company Background: Septerna is a clinical-stage biotechnology firm focused on developing oral small-molecule therapies targeting G protein-coupled receptors, currently collaborating with Novo Nordisk to develop treatment candidates for obesity and type 2 diabetes, showcasing its potential in addressing complex disease treatments.
See More
Septerna Executive Sells Shares to Supplement Income
- Transaction Overview: On June 22, 2026, Daniel D. Long, SVP of Septerna, exercised and sold 15,000 shares of common stock for approximately $533,000 at a weighted average price of $35.51 per share, impacting 13.46% of his direct holdings and reducing his position to 96,412 shares.
- Execution Method: The transaction was executed directly through option exercise followed by immediate sale, indicating Long's direct involvement without any indirect entities, although this action does not necessarily reflect confidence in the company's future.
- Company Background and Partnerships: Septerna is a clinical-stage biotechnology firm specializing in oral small-molecule therapies targeting GPCRs, currently collaborating with Novo Nordisk to develop multiple treatment candidates for obesity and type 2 diabetes, among other cardiometabolic diseases.
- Market Performance and Analysis: While Long's stock sale may be aimed at supplementing his income, analysts note that Septerna was not included in The Motley Fool Stock Advisor's list of top investment picks, reflecting a cautious market sentiment regarding its future performance.
See More
Latest Wall Street Ratings Overview
- SpaceX Initiation: New Street initiates SpaceX with a buy rating, projecting a 75% market share in a $2.3 trillion market, suggesting a fair value of $330 per share if the company captures 50% of the high-end market estimate, indicating strong potential in the space industry.
- Intel Double Upgrade: Bank of America upgrades Intel from underperform to buy, citing increased confidence in its opportunities in leading-edge wafers and packaging, which is expected to enhance its share in the larger CPU market, reflecting a positive outlook for the semiconductor sector.
- AMD Price Target Increase: Bank of America raises AMD's price target from $500 to $560, highlighting its leading position in the CPU market and the upcoming AI Day (Venice launch), indicating strong performance driven by technological innovation and market demand.
- Netflix Outperformance: Evercore ISI reiterates Netflix as outperform, with surveys showing robust core metrics in both U.S. and UK markets, particularly in the adoption of ad-supported subscription offerings, demonstrating its solid position in the competitive streaming market.
See More
Septerna Executive Sells Significant Stock Holdings
- Transaction Overview: Chief People Officer Samira Shaikhly sold 11,798 shares of common stock on May 26, 2026, for approximately $355,000, reducing her direct holdings by 93.7% to just 793 shares, indicating a potential lack of confidence in the company's stock.
- Transaction Context: The sale was executed at an average purchase price of $30.06 as per SEC Form 4 and occurred during a period of rising stock prices, reflecting Shaikhly's non-discretionary reduction under a pre-arranged Rule 10b5-1 trading plan.
- Company Financial Health: Septerna reported $522.1 million in cash, cash equivalents, and marketable securities at the end of Q1 2026, providing a runway for operations until at least 2029, although the executive's sell-off may raise concerns about the company's outlook.
- Market Reaction and Outlook: Despite the executive's sell-off, Septerna's stock rose due to positive clinical trial progress, hitting a 52-week high of $37.99 on June 24, indicating market confidence in its future, although analysts have not included it in their top investment picks.
See More
Septerna Executive's Stock Sale Raises Concerns
- Executive Sell-off: Septerna's Chief People Officer Samira Shaikhly sold 11,798 shares of common stock on May 26 for approximately $355,000, resulting in a dramatic 93.70% reduction in her direct holdings from 83,044 to 793 shares, indicating a pressing need for liquidity.
- Transaction Structure: The shares sold were acquired through exercising vested stock options and immediately disposed of in the open market, suggesting that the transaction was structured for liquidity rather than increasing equity exposure, reflecting cautious sentiment from company executives regarding future stock performance.
- Market Performance Impact: Following Shaikhly's sell-off, Septerna's stock price reached a 52-week high of $37.99 on June 24, indicating positive market sentiment driven by the company's clinical trial progress, although the executive's sale may raise investor concerns about the company's outlook.
- Financial Overview: Septerna has a market capitalization of $1.35 billion, with trailing twelve-month revenue of $72.26 million and a net loss of $36.04 million; despite these losses, the company holds $522.1 million in cash and equivalents, sufficient to fund operations at least until 2029, demonstrating financial stability.
See More
Septerna Executive Sells Nearly 12,000 Shares: Implications for Investors
- Executive Sell-off: Samira Shaikhly, Chief People Officer of Septerna, sold 11,798 shares of common stock for approximately $355,000, resulting in a dramatic reduction of her holdings from 83,044 to 793 shares, a decrease of 93.70%, indicating a heightened need for liquidity within the company.
- Transaction Context: The shares were sold after exercising vested stock options, suggesting the transaction was structured for liquidity rather than increasing equity exposure, reflecting a cautious outlook on the company's future stock performance by the executive.
- Company Financials: Septerna has a market capitalization of $1.35 billion, with trailing twelve-month revenue of $72.26 million and a net loss of $36.04 million, highlighting the challenges and opportunities faced by the company in the clinical-stage biotechnology sector.
- Market Reaction and Outlook: Despite the executive sell-off, Septerna's stock price rose following positive clinical trial results, reaching a 52-week high of $37.99 on June 24, indicating market confidence in its future; however, analysts have not included it in their top investment picks.
See More
Septerna Executive Sells Shares, Reduces Holdings by 13.46%
- Transaction Overview: According to an SEC Form 4 filing, Septerna's SVP Daniel D. Long exercised and immediately sold 15,000 shares of Common Stock on June 22, 2026, with a transaction value of approximately $533,000, indicating executive liquidity management.
- Change in Holdings: This transaction reduced Long's direct holdings from 111,412 shares to 96,412 shares, a decrease of 13.46%, while indirect holdings remained at zero, reflecting a strategic adjustment in executive stock management.
- Continued Equity Exposure: Post-transaction, Long retains 96,412 shares of Common Stock and approximately 36,000 unexercised stock options, indicating ongoing confidence in Septerna despite the reduction in direct holdings.
- Company Background: Septerna is a clinical-stage biotechnology firm focused on developing oral small-molecule therapies targeting G protein-coupled receptors, currently collaborating with Novo Nordisk to develop treatment candidates for obesity and type 2 diabetes, showcasing its potential in addressing complex disease treatments.
See More
Septerna Executive Sells Shares to Supplement Income
- Transaction Overview: On June 22, 2026, Daniel D. Long, SVP of Septerna, exercised and sold 15,000 shares of common stock for approximately $533,000 at a weighted average price of $35.51 per share, impacting 13.46% of his direct holdings and reducing his position to 96,412 shares.
- Execution Method: The transaction was executed directly through option exercise followed by immediate sale, indicating Long's direct involvement without any indirect entities, although this action does not necessarily reflect confidence in the company's future.
- Company Background and Partnerships: Septerna is a clinical-stage biotechnology firm specializing in oral small-molecule therapies targeting GPCRs, currently collaborating with Novo Nordisk to develop multiple treatment candidates for obesity and type 2 diabetes, among other cardiometabolic diseases.
- Market Performance and Analysis: While Long's stock sale may be aimed at supplementing his income, analysts note that Septerna was not included in The Motley Fool Stock Advisor's list of top investment picks, reflecting a cautious market sentiment regarding its future performance.
See More
Latest Wall Street Ratings Overview
- SpaceX Initiation: New Street initiates SpaceX with a buy rating, projecting a 75% market share in a $2.3 trillion market, suggesting a fair value of $330 per share if the company captures 50% of the high-end market estimate, indicating strong potential in the space industry.
- Intel Double Upgrade: Bank of America upgrades Intel from underperform to buy, citing increased confidence in its opportunities in leading-edge wafers and packaging, which is expected to enhance its share in the larger CPU market, reflecting a positive outlook for the semiconductor sector.
- AMD Price Target Increase: Bank of America raises AMD's price target from $500 to $560, highlighting its leading position in the CPU market and the upcoming AI Day (Venice launch), indicating strong performance driven by technological innovation and market demand.
- Netflix Outperformance: Evercore ISI reiterates Netflix as outperform, with surveys showing robust core metrics in both U.S. and UK markets, particularly in the adoption of ad-supported subscription offerings, demonstrating its solid position in the competitive streaming market.
See More
